Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

Shares of Apellis Pharmaceuticals (NASDAQ: APLS) are down by about 62% from the peak they reached in January. However, ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

Thus, even though Syfovre has a competitive advantage over Izervay, William Blair believes both medications can thrive in light of the extensive market, significant unmet needs, and the absence of ...

Moreover, the outlook for Syfovre is not promising ... Additionally, the anticipated market share gains by Izervay pose a significant challenge, and price discounts are not fully factored in ...

According to the analyst, Syfovre presents a more attractive efficacy profile and a more advantageous label, permitting monthly or bi-monthly dosing and treatment beyond 12 months (although the label ...

LumiThera's Valeda Light Delivery System generates light at different wavelengths to stimulate and improve the function of retinal mitochondria. The photobiomodulation (PBM) system is the first ...